Jim Simons Precipio, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.33 - $0.7 $3,266 - $6,929	9,899 Added 25.29%	49,044 $19,000
Q1 2023 May 12, 2023	BUY	$0.6 - $1.0 $9,207 - $15,345	15,345 Added 64.47%	39,145 $26,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $17.4 $400 - $13,919	800 Added 3.48%	23,800 $13,000
Q3 2022 Nov 14, 2022	BUY	$0.78 - $17.8 $2,184 - $49,840	2,800 Added 13.86%	23,000 $18,000
Q2 2022 Aug 12, 2022	BUY	$0.98 - $1.68 $19,796 - $33,936	20,200 New	20,200 $21,000
Q4 2021 Feb 11, 2022	SELL	$1.58 - $2.77 $111,232 - $195,008	-70,400 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$2.78 - $3.63 $399,208 - $521,268	-143,600 Reduced 67.1%	70,400 $199,000
Q2 2021 Aug 13, 2021	SELL	$1.8 - $5.25 $219,960 - $641,550	-122,200 Reduced 36.35%	214,000 $777,000
Q1 2021 May 13, 2021	BUY	$2.1 - $3.89 $513,660 - $951,494	244,600 Added 267.03%	336,200 $777,000
Q4 2020 Feb 10, 2021	BUY	$1.94 - $2.64 $177,704 - $241,824	91,600 New	91,600 $190,000
Q2 2020 Aug 13, 2020	SELL	$0.58 - $1.51 $47,386 - $123,367	-81,700 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.68 - $2.3 $55,556 - $187,910	81,700 New	81,700 $57,000

340

Ticker PRPO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 22,736,500
Market Cap $150M
Description
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust geneti...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.